Clinical trial NCT05968235: Correlation of Glucose and Lipid Metabolism Levels With Vitiligo
Official title: Association of Glucose and Lipid Metabolism Levels and Vitiligo : a Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Metabolism Disorder, Glucose
Metabolism Disorder, Lipid
Vitiligo
Keywords: Vitiligo
Glucose
Lipid
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 963
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: We recruited patients with clinically diagnosed vitiligo and age- and sex-matched healthy volunteers.

Brief summary: The goal of this observational study is to compare serum glucose and lipid metabolism levels between health volunteers and vitiligo patients. The main question it aims to answer is whether vitiligo is related to glucose and lipid metabolism disorders. Participants will complete a vitiligo questionnaire and test serum levels of indicators related to glucose and lipid metabolism. Researchers will compare vitiligo patients with healthy volunteers to see if there is a correlation between vitiligo and disorders of glucose and lipid metabolism.

Detailed description: Vitiligo is a common autoimmune skin disease, which causes white spot formation due to destruction of epidermal melanocytes, severely affecting the physical and mental health of patients, but treatment is extremely difficult due to unclear pathogenesis. Studies have reported that patients with type I diabetes mellitus combined with vitiligo, the risk of metabolic syndrome, diabetes mellitus, elevated lipids, and obesity in vitiligo patients is higher than that of healthy controls, and other studies have reported that vitiligo lesions in patients with hypercholesterolemia combined with vitiligo treated with simvastatin get rapid skin color, suggesting that there is a correlation between glucose and lipid metabolism and the vitiligo disease, but as of now there is no research study on the correlation of glucose and lipid metabolism and vitiligo pathogenesis, much less large data can be analyzed for reference. Therefore, there is an urgent need to study the metabolic profile of vitiligo patients and utilize the basic research platform to explore the role of abnormal body metabolism in the onset or progression of vitiligo.

This study intends to conduct a cross-sectional study, using questionnaires to collect and register vitiligo patients' disease information, etc., to establish a database of study subjects, and to collect peripheral blood samples from vitiligo patients to test the levels of key indicators of glycolipid and lipid metabolism, and to analyze their correlation with clinical features, disease activity, and treatment of vitiligo. Through the above studies, clinical evidence for the involvement of abnormalities in glycolipid and lipid metabolism in the development of vitiligo was provided.

Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed as vitiligo by a dermatologist based on a combination of clinical manifestations (milky white or porcelain white patches), Wood's Lamp test results (bright white fluorescence), and histopathologic test results (reduction or disappearance of epidermal melanocytes in the white patches);
2. Male or female subjects, age between 18 and 60 years old;
3. Stable vital signs;
4. Study subjects voluntarily signed an informed consent form.

Exclusion Criteria:

1. Subjects who have been systematically using glucocorticoids, immunosuppressants, etc. that affect glycolipid levels due to a combination of diseases other than metabolic diseases in the last 3 months shall be asked and determined by a clinician;
2. Women who are pregnant or breastfeeding shall be asked and determined by a clinician;
3. Subjects who suffer from psychiatric disorders, etc. and who are not capable of cooperating with the follow-up study shall be asked and determined by a clinician.

Primary outcomes:
measure: Demographic and epidemiological information of the study subjects
timeFrame: 2020.02.01-2023.03.25
measure: Serum glucose and lipid metabolism levels of the study subjects
timeFrame: 2020.02.01-2023.03.25
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
affiliation: Air Force Military Medical University, China
name: Chunying Li
role: PRINCIPAL_INVESTIGATOR
References: